Advertisement

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov December 1 2017 7 (12) 1355-1357; DOI:10.1158/2159-8290.CD-ITI7-12

In the Spotlight

Review

Research Brief

  • Research Brief
    Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
    Aadel A. Chaudhuri, Jacob J. Chabon, Alexander F. Lovejoy, Aaron M. Newman, Henning Stehr, Tej D. Azad, Michael S. Khodadoust, Mohammad Shahrokh Esfahani, Chih Long Liu, Li Zhou, Florian Scherer, David M. Kurtz, Carmen Say, Justin N. Carter, David J. Merriott, Jonathan C. Dudley, Michael S. Binkley, Leslie Modlin, Sukhmani K. Padda, Michael F. Gensheimer, Robert B. West, Joseph B. Shrager, Joel W. Neal, Heather A. Wakelee, Billy W. Loo Jr, Ash A. Alizadeh and Maximilian Diehn
    Cancer Discov December 1 2017 7 (12) 1394-1403; DOI:10.1158/2159-8290.CD-17-0716

    ctDNA profiling of pre- and post-treatment samples from patients with localized lung cancer identifies the presence of minimal residual disease earlier than standard imaging.

Research Articles

  • Research Articles
    Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
    Juliane Gust, Kevin A. Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F. Gonzalez-Cuyar, Cecilia Yeung, W. Conrad Liles, Mark Wurfel, Jose A. Lopez, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Tahsin Özpolat, Kathleen R. Fink, Stanley R. Riddell, David G. Maloney and Cameron J. Turtle
    Cancer Discov December 1 2017 7 (12) 1404-1419; DOI:10.1158/2159-8290.CD-17-0698

    Endothelial activation and vascular disruption were associated with a high risk of severe neurotoxicity in 133 patients with B-cell malignancies treated with CD19-targeted CAR-T cell therapy.

  • Research Articles
    Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
    Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y. Du, Joseph Schlessinger, Sarah B. Goldberg, Anne Chiang, Miguel F. Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M. Montuenga, Richard Lifton, Soldano Ferrone, Paula Kavathas, David L. Rimm, Susan M. Kaech, Kurt Schalper, Roy S. Herbst and Katerina Politi
    Cancer Discov December 1 2017 7 (12) 1420-1435; DOI:10.1158/2159-8290.CD-17-0593

    Analysis of immune checkpoint inhibitor–resistant lung tumors revealed that loss of B2M expression may impair antigen processing to promote acquired resistance in patients with lung cancer.

  • Research Articles
    A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors
    Xuesong Zhao, Ekaterina Pak, Kimberly J. Ornell, Maria F. Pazyra-Murphy, Ethan L. MacKenzie, Emily J. Chadwick, Tatyana Ponomaryov, Joseph F. Kelleher and Rosalind A. Segal
    Cancer Discov December 1 2017 7 (12) 1436-1449; DOI:10.1158/2159-8290.CD-17-0281

    Mutations that result in loss of primary cilia promote resistance to SMO inhibitors by eliminating formation of the GLI2 repressor form, allowing persistent low-level activation of hedgehog signaling.

  • Research Articles | AuthorChoice
    mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors
    Clare F. Malone, Chloe Emerson, Rachel Ingraham, William Barbosa, Stephanie Guerra, Haejin Yoon, Lin L. Liu, Franziska Michor, Marcia Haigis, Kay F. Macleod, Ophélia Maertens and Karen Cichowski
    Cancer Discov December 1 2017 7 (12) 1450-1463; DOI:10.1158/2159-8290.CD-17-0177

    Combined treatment with mTOR and HDAC inhibitors cooperatively suppresses thioredoxin to trigger excessive oxidative stress and induce cell death in NF1- and KRAS-mutant tumors

  • Research Articles
    Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers
    Laetitia Seguin, Maria F. Camargo, Hiromi I. Wettersten, Shumei Kato, Jay S. Desgrosellier, Tami von Schalscha, Kathryn C. Elliott, Erika Cosset, Jacqueline Lesperance, Sara M. Weis and David A. Cheresh
    Cancer Discov December 1 2017 7 (12) 1464-1479; DOI:10.1158/2159-8290.CD-17-0539

    Inhibiting galectin-3 disrupts its interaction with integrin αvβ3, preventing the association with mutant KRAS to reduce macropinocytosis, increase ROS, and suppress KRAS-mutant tumor growth and progression.

News in Brief

Research Watch

Back to top

Jump to

Advertisement